The model by Weimer et al. [30] used disease progression data from a single study of 134 patients on cholinesterase inhibitors [45].
This paper is a report of a study that aimed to examine factors connected to progression and attrition by mapping student characteristics against Year 1 progression data.
The work presented here enhances the methodology proposed in previous papers by extending the Bayesian framework to multiple damage mechanisms, and validates the approach using damage progression data from notched cross-ply CFRP coupons subject to tension-tension fatigue.
Career progression data could also be used by schools to present a local dimension to national and regional labor market information as well as highlight many different routes to successful careers.
We advocate the creation of progression endpoints that utilize all available progression data rather than early fixed timepoint analyses and show that little is to be gained by assessing progression status any more frequently than would be required in routine clinical practice.
Performing immunohistochemistry, Treg could hardly be detected on serial sections during the phase of disease progression (data not shown).
In addition, we also summarized cancer progression data across rat and mouse to contrast subtle differences in the severity of adverse chronic outcomes.
Where we could make comparisons using the incomplete Gag sequence data, there was no apparent correlation between viral sequence diversity and HIV disease progression (data not shown).
Although vvirus related factors have been proposed as influencing disease progression, data from recent pandemic H1N1 2009 influenza shows that the similar viral loads were found in the infected hosts regardless of disease severity [2], [3].
Since this system is artificial and the endogenous XIAP protein level was not changed during cell cycle progression (data not shown), it is not clear whether XIAP itself contributes to the cell cycle progression through the inhibition of caspase activities.
Therefore, the suggestion that ERK1 may act as a negative modulator of cell proliferation [19] in combination with our finding that activated ERK1 is also present during overexpression of p19 (Figure 1F), fits in well with the cell cycle progression data found for overexpression of p19 reported here.
